share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024財年三季報
美股SEC公告 ·  11/20 02:16

Moomoo AI 已提取核心訊息

FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.
FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.
FOXO Technologies Inc.（FOXO）報告稱，截至2024年9月30日的季度淨收入同比大幅增加，主要是由於收購了Myrtle和RCHI。淨收入上升至$119.6萬，而去年同期爲$1萬。營業費用減少了37％，其中銷售、一般和管理費用下降了63％。公司的淨虧損改善了47％，FOXO的淨虧損爲$194.6萬。由於較高的利息支出，非營業費用增加。公司的流動性狀況仍然令人擔憂，報告了營運資本虧損和總股東權益虧損。FOXO繼續尋求額外的資金支持運營，並通過各種債務融資籌集資金。包括Myrtle和RCHI的醫療保健部門爲淨收入貢獻了$118.8萬，而實驗室和生命科學部門的收入略微下降。公司的未來業績受到經濟狀況、醫療改革以及吸引和留住合格醫療專業人員的能力等風險的影響。
FOXO Technologies Inc.（FOXO）報告稱，截至2024年9月30日的季度淨收入同比大幅增加，主要是由於收購了Myrtle和RCHI。淨收入上升至$119.6萬，而去年同期爲$1萬。營業費用減少了37％，其中銷售、一般和管理費用下降了63％。公司的淨虧損改善了47％，FOXO的淨虧損爲$194.6萬。由於較高的利息支出，非營業費用增加。公司的流動性狀況仍然令人擔憂，報告了營運資本虧損和總股東權益虧損。FOXO繼續尋求額外的資金支持運營，並通過各種債務融資籌集資金。包括Myrtle和RCHI的醫療保健部門爲淨收入貢獻了$118.8萬，而實驗室和生命科學部門的收入略微下降。公司的未來業績受到經濟狀況、醫療改革以及吸引和留住合格醫療專業人員的能力等風險的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    OneMedNet
    ONMD
    -- 1.400
    SCWorx
    WORX
    -- 1.6100
    Aclarion
    ACON
    -- 0.1249
    DarioHealth
    DRIO
    -- 0.800
    Streamline Health Solutions
    STRM
    -- 3.390

    解鎖榜首股票